Biomarkers such as intertumoral PD‐L1 expression, tumor mutation burden (TMB), tumor‐infiltrating T lymphocytes (TILs) and neoantigens have been identified to predict the efficacy of ICIs,4, 5, 6 but the clinical predictive values are not entirely consistent. This evidence concerns the gene CD274 and neoplasm.